Reunion Neuroscience, Inc.
@reunionneuro.bsky.social
Reunion is committed to innovating therapeutic solutions to treat mental health conditions through the development of novel psychedelic compounds.
www.reunionneuro.com
www.reunionneuro.com
Reunion Neuroscience welcomes Dr. Sahil V. Kirpekar as President and CEO. Sahil will help guide the company in its mission to revolutionize the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions. bit.ly/4vmJ6xS
June 15, 2026 at 5:41 PM
Reunion Neuroscience welcomes Dr. Sahil V. Kirpekar as President and CEO. Sahil will help guide the company in its mission to revolutionize the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions. bit.ly/4vmJ6xS
At #ASCP, our CMO Mark Pollack, MD, spoke with @PsychTimes on Phase 2 RECONNECT results of Luvesilocin in postpartum depression showing rapid improvement, 1 week efficacy, and durability through Day 28. Watch here: bit.ly/4o5ZUqp
June 4, 2026 at 7:04 PM
At #ASCP, our CMO Mark Pollack, MD, spoke with @PsychTimes on Phase 2 RECONNECT results of Luvesilocin in postpartum depression showing rapid improvement, 1 week efficacy, and durability through Day 28. Watch here: bit.ly/4o5ZUqp
We’re pleased to share CEO Greg Mayes will speak today at the Psychedelic Medicine Coalition Federal Summit on “Psychedelic Medicine Comes of Age,” joining leaders advancing new mental health therapies and shaping the future of care. #MentalHealth #PsychedelicMedicine
May 14, 2026 at 1:37 PM
We’re pleased to share CEO Greg Mayes will speak today at the Psychedelic Medicine Coalition Federal Summit on “Psychedelic Medicine Comes of Age,” joining leaders advancing new mental health therapies and shaping the future of care. #MentalHealth #PsychedelicMedicine
Excited to present full Phase 2 RECONNECT results of luvesilocin in postpartum depression at #ASCP2026 & #APA2026. Met primary endpoint with meaningful MADRS reduction by Day 7, seen Day 1 and sustained to Day 28. Supports FDA path + Breakthrough status. Learn more: bit.ly/4dfGR7J
May 11, 2026 at 12:21 PM
Excited to present full Phase 2 RECONNECT results of luvesilocin in postpartum depression at #ASCP2026 & #APA2026. Met primary endpoint with meaningful MADRS reduction by Day 7, seen Day 1 and sustained to Day 28. Supports FDA path + Breakthrough status. Learn more: bit.ly/4dfGR7J
Today is World Maternal Mental Health Day, a time to spotlight support for moms during pregnancy, postpartum, and beyond. At Reunion Neuroscience, we’re advancing postpartum depression research to help shape the future of care. #WorldMaternalMentalHealthDay #MaternalMentalHealth
May 7, 2026 at 12:10 PM
Today is World Maternal Mental Health Day, a time to spotlight support for moms during pregnancy, postpartum, and beyond. At Reunion Neuroscience, we’re advancing postpartum depression research to help shape the future of care. #WorldMaternalMentalHealthDay #MaternalMentalHealth
Our President & CEO Greg Mayes and Dr. Manish Agrawal joined the Empowered Patient Podcast to discuss adjustment disorder in cancer care and our REKINDLE Phase 2 study of luvesilocin, a psilocybin analog.🎙️ Listen: bit.ly/4c3LC52
Empowered Patient Podcast: Psychedelic Treatment for Adjustment Disorder in Cancer Patients with Greg Mayes Reunion Neuroscience and Dr. Manish Agrawal Sunstone Therapies
Greg Mayes, President and CEO of Reunion Neuroscience, and Dr. Manish Agrawal, the Co-Founder and CEO of Sunstone Therapies, shine a light on adjustment disorder, a disproportionate emotional or behav...
bit.ly
March 25, 2026 at 5:39 PM
Our President & CEO Greg Mayes and Dr. Manish Agrawal joined the Empowered Patient Podcast to discuss adjustment disorder in cancer care and our REKINDLE Phase 2 study of luvesilocin, a psilocybin analog.🎙️ Listen: bit.ly/4c3LC52
Dr. Manish Agrawal, a PI in our REKINDLE Phase 2 study, appeared on WUSA TV’s Great Day Washington to discuss the importance of emotional health in cancer care and the need for better treatments for adjustment disorder. Watch the segment here: www.wusa9.com/video/entert...
Redefining cancer care: addressing adjustment disorder and emotional health
Sponsored by: Reunion Neuroscience. Manish Agrawal, MD, is a DC–based leader in oncology. To learn more go to rekindlestudies.com.
www.wusa9.com
February 26, 2026 at 8:58 PM
Dr. Manish Agrawal, a PI in our REKINDLE Phase 2 study, appeared on WUSA TV’s Great Day Washington to discuss the importance of emotional health in cancer care and the need for better treatments for adjustment disorder. Watch the segment here: www.wusa9.com/video/entert...
Reunion Neuroscience has received FDA Breakthrough Therapy Designation for luvesilocin for postpartum depression, supported by strong Phase 2 data showing rapid, durable improvement. This milestone moves us toward Phase 3 in 2026. Read more: bit.ly/4s5A1HW
February 23, 2026 at 1:23 PM
Reunion Neuroscience has received FDA Breakthrough Therapy Designation for luvesilocin for postpartum depression, supported by strong Phase 2 data showing rapid, durable improvement. This milestone moves us toward Phase 3 in 2026. Read more: bit.ly/4s5A1HW
Reunion will participate in several upcoming investor conferences, sharing updates on our clinical progress and vision for next gen psychedelic inspired therapies for underserved mental health disorders. Full release: bit.ly/4kMzrwr
February 19, 2026 at 2:06 PM
Reunion will participate in several upcoming investor conferences, sharing updates on our clinical progress and vision for next gen psychedelic inspired therapies for underserved mental health disorders. Full release: bit.ly/4kMzrwr
At ACNP, we shared full Phase 2 data for RE104 in postpartum depression. RECONNECT showed rapid, durable improvements starting Day 1 and through Day 28. With FDA alignment on the path ahead, we plan to begin Phase 3 in 2026. Learn more: bit.ly/4pQYEqe
January 20, 2026 at 1:28 PM
At ACNP, we shared full Phase 2 data for RE104 in postpartum depression. RECONNECT showed rapid, durable improvements starting Day 1 and through Day 28. With FDA alignment on the path ahead, we plan to begin Phase 3 in 2026. Learn more: bit.ly/4pQYEqe
Exciting updates from Reunion Neuroscience! Entering 2026 with momentum as we advance RE104: Phase 3 in PPD, Phase 2 in AjD & GAD. Learn more about our vision for mental health care: bit.ly/4pvVOqF
January 12, 2026 at 1:23 PM
Exciting updates from Reunion Neuroscience! Entering 2026 with momentum as we advance RE104: Phase 3 in PPD, Phase 2 in AjD & GAD. Learn more about our vision for mental health care: bit.ly/4pvVOqF
November is Lung Cancer Awareness Month. We're honoring those affected and exploring new ways to support emotional health. Our REKINDLE trial studies RE104, a psychedelic-inspired therapy for Adjustment Disorder in cancer patients. Learn more: rekindlestudies.com #LungCancerAwarenessMonth
November 3, 2025 at 2:07 PM
November is Lung Cancer Awareness Month. We're honoring those affected and exploring new ways to support emotional health. Our REKINDLE trial studies RE104, a psychedelic-inspired therapy for Adjustment Disorder in cancer patients. Learn more: rekindlestudies.com #LungCancerAwarenessMonth
It’s a time to honor the strength of those impacted by breast cancer, and to recognize that healing goes beyond the physical. Our REKINDLE Ph 2 trial is exploring RE104, a psychedelic-inspired therapeutic, for AjD in patients with cancer & other serious illnesses. REKINDLE study: rekindlestudies.com
October 17, 2025 at 12:49 PM
It’s a time to honor the strength of those impacted by breast cancer, and to recognize that healing goes beyond the physical. Our REKINDLE Ph 2 trial is exploring RE104, a psychedelic-inspired therapeutic, for AjD in patients with cancer & other serious illnesses. REKINDLE study: rekindlestudies.com
Today, we announced the dosing of the first patient in REKINDLE, our Ph 2 clinical trial evaluating RE104 for the treatment of adjustment disorder (AjD) in patients with cancer and other serious medical conditions.
Read the release: bit.ly/3KsOU6M
#psychedelictherapeutics #adjustmentdisorder
Read the release: bit.ly/3KsOU6M
#psychedelictherapeutics #adjustmentdisorder
September 30, 2025 at 12:06 PM
Today, we announced the dosing of the first patient in REKINDLE, our Ph 2 clinical trial evaluating RE104 for the treatment of adjustment disorder (AjD) in patients with cancer and other serious medical conditions.
Read the release: bit.ly/3KsOU6M
#psychedelictherapeutics #adjustmentdisorder
Read the release: bit.ly/3KsOU6M
#psychedelictherapeutics #adjustmentdisorder
Are you attending the 8th Annual Maternal Mental Health Symposium? Camille Hoffman, MD, MSCS, lead investigator in our RECONNECT trial, will be presenting clinical insights on RE104, our novel psychedelic therapy for #postpartumdepression. Registration is FREE for this virtual event!
September 22, 2025 at 5:06 PM
Are you attending the 8th Annual Maternal Mental Health Symposium? Camille Hoffman, MD, MSCS, lead investigator in our RECONNECT trial, will be presenting clinical insights on RE104, our novel psychedelic therapy for #postpartumdepression. Registration is FREE for this virtual event!
Today, we announced the final closing of our Series A Financing and shared plans to advance RE104 into clinic development for the treatment of Generalized Anxiety Disorder (GAD).
Read the full release for more specifics: bit.ly/48icPPS
#mentalhealth #clinicaldevelopment #innovation
Read the full release for more specifics: bit.ly/48icPPS
#mentalhealth #clinicaldevelopment #innovation
September 16, 2025 at 11:53 AM
Today, we announced the final closing of our Series A Financing and shared plans to advance RE104 into clinic development for the treatment of Generalized Anxiety Disorder (GAD).
Read the full release for more specifics: bit.ly/48icPPS
#mentalhealth #clinicaldevelopment #innovation
Read the full release for more specifics: bit.ly/48icPPS
#mentalhealth #clinicaldevelopment #innovation
Today, we announced positive topline results in our RECONNECT Ph 2 trial, representing a meaningful breakthrough and new hope for women with postpartum depression (#PPD). Explore the full data and outcomes in the news release: bit.ly/45Ty3lw
#postpartumdepression #maternalmentalhealth
#postpartumdepression #maternalmentalhealth
August 18, 2025 at 11:50 AM
Today, we announced positive topline results in our RECONNECT Ph 2 trial, representing a meaningful breakthrough and new hope for women with postpartum depression (#PPD). Explore the full data and outcomes in the news release: bit.ly/45Ty3lw
#postpartumdepression #maternalmentalhealth
#postpartumdepression #maternalmentalhealth
Our manuscript entitled “Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study,” has published in Journal of Clinical Psychopharmacology. See release news here: bit.ly/4lJJnq2
July 22, 2025 at 1:36 PM
Our manuscript entitled “Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study,” has published in Journal of Clinical Psychopharmacology. See release news here: bit.ly/4lJJnq2
The public version of the Women's Health article is here! You don't want to miss out on Lawrence Leeman, MD discussing our leading single-dose psychedelic therapy, RE104, currently being evaluated in our RECONNECT Ph 2 clinical trial for women battling #ppd. Check it out here: bit.ly/3IcmkFA
July 9, 2025 at 6:12 PM
The public version of the Women's Health article is here! You don't want to miss out on Lawrence Leeman, MD discussing our leading single-dose psychedelic therapy, RE104, currently being evaluated in our RECONNECT Ph 2 clinical trial for women battling #ppd. Check it out here: bit.ly/3IcmkFA
Thank you to Maria Shriver and the NBCNews Today Show for the opportunity to bring awareness to our new potential therapy for mothers battling #PPD. We appreciate Melissa Lavasani & Keith Heinzerling for their personal & professional contributions to this cause. View here: bit.ly/3Gc5CFB
June 25, 2025 at 9:20 PM
Thank you to Maria Shriver and the NBCNews Today Show for the opportunity to bring awareness to our new potential therapy for mothers battling #PPD. We appreciate Melissa Lavasani & Keith Heinzerling for their personal & professional contributions to this cause. View here: bit.ly/3Gc5CFB
🚨Attention🚨 Be sure to tune in to the Today Show on @NBCNews tomorrow (June 25) at 8am ET to see our interview with @Maria Shriver on #maternalmentalhealth and #postpartumdepression. See you there!
June 24, 2025 at 10:23 PM
🚨Attention🚨 Be sure to tune in to the Today Show on @NBCNews tomorrow (June 25) at 8am ET to see our interview with @Maria Shriver on #maternalmentalhealth and #postpartumdepression. See you there!
Are you attending Psychedelic Science 2025? Our SVP of Clinical Development & Regulatory Affairs, Beatrix Taylor, MSc, RAC, will be presenting an update on our RECONNECT Ph 2 study in #PPD, and the study design for our upcoming REKINDLE Ph 2 trial in #adjustment disorder. #PS2025 #PsychSci
June 11, 2025 at 1:11 PM
Are you attending Psychedelic Science 2025? Our SVP of Clinical Development & Regulatory Affairs, Beatrix Taylor, MSc, RAC, will be presenting an update on our RECONNECT Ph 2 study in #PPD, and the study design for our upcoming REKINDLE Ph 2 trial in #adjustment disorder. #PS2025 #PsychSci
Are you attending the ASCP Annual Meeting ? Our CMO, Mark Pollack, MD, will present results from our Phase 1 trial of RE104, supporting the advancement of RE104 in our Phase 2 RECONNECT and REKINDLE trials for innovative treatment in PPD and adjustment disorder. #ASCP2025 #mentalhealth
May 22, 2025 at 2:28 PM
Are you attending the ASCP Annual Meeting ? Our CMO, Mark Pollack, MD, will present results from our Phase 1 trial of RE104, supporting the advancement of RE104 in our Phase 2 RECONNECT and REKINDLE trials for innovative treatment in PPD and adjustment disorder. #ASCP2025 #mentalhealth
Big news! We have completed enrollment and dosed our last patient in our RECONNECT Phase 2 clinical trial for the treatment of #pppd, with topline results expected in Q3 2025. #maternalmentalhealth #ppd
Read more here: bit.ly/4jt37fP
Read more here: bit.ly/4jt37fP
May 19, 2025 at 1:46 PM
Big news! We have completed enrollment and dosed our last patient in our RECONNECT Phase 2 clinical trial for the treatment of #pppd, with topline results expected in Q3 2025. #maternalmentalhealth #ppd
Read more here: bit.ly/4jt37fP
Read more here: bit.ly/4jt37fP
We are featured in @womens-healthmag.bsky.social discussing our leading single-dose #psychedelic therapy, RE104, being evaluated in our RECONNECT Ph 2 clinical trial to help provide women suffering from #ppd with a potential new rapid-acting treatment solution. Full article: lnkd.in/eJb36zCn
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
May 15, 2025 at 7:58 PM
We are featured in @womens-healthmag.bsky.social discussing our leading single-dose #psychedelic therapy, RE104, being evaluated in our RECONNECT Ph 2 clinical trial to help provide women suffering from #ppd with a potential new rapid-acting treatment solution. Full article: lnkd.in/eJb36zCn